Back Article

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492

Van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84. https://doi.org/10.1056/NEJMoa1112088

Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68–74. https://doi.org/10.1245/s10434-011-2049-9

Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation therapy oncology group. JAMA. 1999;281(17):1623–7. https://doi.org/10.1001/jama.281.17.1623

Thomsen MS, Berg M, Nielsen HM, Pedersen AN, Overgaard M, Ewertz M, et al. Post-mastectomy radiotherapy in Denmark: from 2D to 3D treatment planning guidelines of the Danish breast cancer cooperative group. Acta Oncol. 2008;47(4):654–61. https://doi.org/10.1080/02841860801975000

Mackley HB, Adelstein JS, Reddy CA, Adelstein DJ, Rice TW, Saxton JP, et al. Choice of radiotherapy planning modality influences toxicity in the treatment of locally advanced esophageal cancer. J Gastrointest Cancer. 2008;39(1–4):130–7. https://doi.org/10.1007/s12029-009-9067-x

Leong J. Use of digital fluoroscopy as an online verification device in radiation therapy. Phys Med Biol. 1986;31(9):985–92. https://doi.org/10.1088/0031-9155/31/9/004

Verellen D, De Ridder M, Storme G, short. A (short) history of image-guided radiotherapy. Radiother Oncol. 2008;86(1):4–13. https://doi.org/10.1016/j.radonc.2007.11.023

Jaffray DA, Siewerdsen JH, Wong JW, Martinez AA. Flat-panel cone-beam computed tomography for image-guided radiation therapy. Int J Radiat Oncol Biol Phys. 2002;53(5):1337–49. https://doi.org/10.1016/s0360-3016(02)02884-5

Rice TW, Ishwaran H, Blackstone EH, Hofstetter WL, Kelsen DP, Apperson-Hansen C, et al. Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016;29(8):913–9. https://doi.org/10.1111/dote.12540

Takahashi N, Umezawa R, Kishida K, Yamamoto T, Ishikawa Y, Takeda K, et al. Clinical outcomes and prognostic factors for esophageal cancer in patients aged 80 years or older who were treated with definitive radiotherapy and chemoradiotherapy. Esophagus. 2022;19(1):129–36. https://doi.org/10.1007/s10388-021-00876-4

Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase Ⅲ trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167–74. https://doi.org/10.1200/JCO.2002.20.5.1167

Hironaka S, Komori A, Machida R, Ito Y, Takeuchi H, Ogawa G, et al. The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage Ⅱ/Ⅲ esophageal cancer: an exploratory analysis of JCOG0909. Esophagus. 2020;17(4):417–24. https://doi.org/10.1007/s10388-020-00741-w

Buckstein M, Liu J. Cervical esophageal cancers: challenges and opportunities. Curr Oncol Rep. 2019;21(5):46. https://doi.org/10.1007/s11912-019-0801-7

Kato K, Ito Y, Nozaki I, Daiko H, Kojima T, Yano M, et al. Parallel-group controlled trial of surgery versus chemoradiotherapy in patients with stage Ⅰ esophageal squamous cell carcinoma. Gastroenterology. 2021;161(6):1878–86.e2. https://doi.org/10.1053/j.gastro.2021.08.007

Nemoto K, Matsumoto Y, Yamakawa M, Jo S, Ito Y, Oguchi M, et al. Treatment of superficial esophageal cancer by external radiation therapy alone: results of a multi-institutional experience. Int J Radiat Oncol Biol Phys. 2000;46(4):921–5. https://doi.org/10.1016/s0360-3016(99)00485-x

Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014;15(3):305–14. https://doi.org/10.1016/S1470-2045(14)70028-2

Moreno AC, Verma V, Hofstetter WL, Lin SH. Patterns of care and treatment outcomes of elderly patients with stage Ⅰ esophageal cancer: analysis of the national cancer data base. J Thorac Oncol. 2017;12(7):1152–60. https://doi.org/10.1016/j.jtho.2017.04.004

Ji Y, Du X, Zhu W, Yang Y, Ma J, Zhang L, et al. Efficacy of concurrent chemoradiotherapy with S-1 vs radiotherapy alone for older patients with esophageal cancer: a multicenter randomized phase 3 clinical trial. JAMA Oncol. 2021;7(10):1459–66. https://doi.org/10.1001/jamaoncol.2021.2705

National comprehensive cancer Network. Available form: https://www.nccn.org/guidelines/category_1

Jones CM, Spencer K, Hitchen C, Pelly T, Wood B, Hatfield P, et al. Hypofractionated radiotherapy in oesophageal cancer for patients unfit for systemic therapy: a retrospective single-centre analysis. Clin Oncol. 2019;31(6):356–64. https://doi.org/10.1016/j.clon.2019.01.010